On September 30, 2008 Chapel Hill, NC and Charlottesville, VA, Cempra Pharmaceuticals, Inc., and Biovista, Inc., announced that they have entered into a research agreement to systematically identify and profile adverse event associations for members of the macrolide drug class. The data generated will be used to better understand the unique benefit/risk characteristics of this important group of antimicrobial drugs, thereby helping to adapt and optimize future clinical trial designs.

"This collaboration with Biovista is a significant step forward in understanding macrolide safety profiles in a way that will help us further our clinical development plans, and ultimately further our goal to bring much-needed antimicrobial and therapeutic drugs to market" said Prabha Fernandes, president and CEO of Cempra.

Read more: http://www.biovista.com/news.php?article_id=125